Price movement over the last 24 hours
ADMA Biologics Inc vs Kaltura Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Kaltura Inc trades at $1.25 (market cap $193.23M). The key difference: ADMA Biologics Inc is far larger — about 11× Kaltura Inc's market cap. Which is the better fit depends on your goals.
| ADMA | KLTR | |
|---|---|---|
Market Cap | $2.13B | $193.23M |
Sector | Health | Technology |
52-Week High | $20.38 | $2.01 |
52-Week Low | $7.60 | $1.08 |
Enterprise Value | $2.20B | $175.95M |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Kaltura (KLTR) trades at $1.29, up 2.38% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $180M and narrowing losses, though it remains unprofitable with negative margins. Recent industry recognition and AI product launches highlight strategic positioning in digital experience platforms.
Investment outlook balances operational improvements against persistent profitability challenges. Positive analyst sentiment (44% buy ratings) and strong institutional coverage suggest potential upside if AI initiatives drive growth, but high P/B ratio and negative cash flow pose risks for near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →